Exploiting the promiscuity of imatinib.
- Author(s): Lee, Shun J;
- Wang, Jean YJ
- et al.
Published Web Locationhttps://doi.org/10.1186/jbiol134
The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 A crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.